Details

Slovenija in Schengen : diplomsko delo visokošolskega programa
ID Kukec, Tina (Author), ID Debelak, Slavko (Mentor) More about this mentor... This link opens in a new window

.pdfPDF - Presentation file, Download (367,26 KB)
MD5: 28F730A0B9186101EAD7EC3E5619131C
PID: 20.500.12556/rul/97535167-b9b5-4ade-9634-6cbe84dff9e6

Language:Slovenian
Keywords:schengenski sporazum, meje, mejna kontrola, državne meje, schengenski informacijski sistem, Slovenija, diplomske naloge
Work type:Undergraduate thesis
Typology:2.11 - Undergraduate Thesis
Organization:FU - Faculty of Administration
Place of publishing:Ljubljana
Publisher:[T. Kukec]
Year:2009
Number of pages:V, 51 f.
PID:20.500.12556/RUL-2129 This link opens in a new window
UDC:341.222(497.4)(043.2)
COBISS.SI-ID:3140014 This link opens in a new window
Publication date in RUL:11.07.2014
Views:3847
Downloads:653
Metadata:XML DC-XML DC-RDF
:
KUKEC, Tina, 2009, Slovenija in Schengen : diplomsko delo visokošolskega programa [online]. Bachelor’s thesis. Ljubljana : T. Kukec. [Accessed 24 March 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=2129
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Proučevanje izražanja gena za fosfatidiletanolamin-N-metiltransferazo v nedrobnoceličnem pljučnem rakavem tkivu
  4. Uporabnost imunohistokemičnega določanja mutacij receptorja za epidermalni rastni faktor pri raku pljuč
  5. Sladkorna bolezen in športna vadba
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back